VJ/OA Journal Club: LITESPARK 005 with Dr. Brian Rini & Dr. Tom Powles (KidneyCancer)

The phase 3 LITESPARK-005 trial evaluated patient-reported outcomes (PROs) for belzutifan, a HIF-2α inhibitor, versus everolimus in patients with advanced renal cell carcinoma previously treated with immune checkpoint and anti-angiogenic therapy.